NCT03466086已完成4 期
Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 1
- 主要终点
- Ocular Comfort
研究概览
简要总结
This clinical study is a randomized, double-masked, cross-over, bilateral, 2 treatment x 2 period, dispensing 4-visit study with a 7-9 day washout period in between visits 2 and 3. The study will last approximately 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Potential subjects must satisfy all the following criteria to be enrolled in the study:
- •Subjects must be at least 18 years of age and no more than 69 years of age (inclusive)
- •Subjects must be non-contact lens wearers
- •Subjects must have a DEQ-5 score of >6 at either Visit 0 (pre-screen) and/or Visit 1 (screening).
- •Subjects must achieve visual acuity of 20/30 (equivalent to 0.18 logMAR) or better in each eye, either unaided or best corrected.
- •Subjects must possess a functional/usable pair of spectacles and bring them to every visit (only if applicable - to the investigators discretion).
- •Subjects must read, understand, and sign the Statement of Informed Consent.
- •Subjects must appear able and willing to adhere to the instructions set forth in this clinical protocol
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Currently pregnant or breast-feeding.
- •Any ocular or systemic allergies or disease which may interfere with the clinical trial (at the investigator's discretion).
- •Any systemic disease, autoimmune disease, or use of medication which may interfere with the clinical trial (at the investigator's discretion).
- •Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report
- •Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA scale
- •Any active ocular abnormalities/conditions that may interfere with the clinical trial (this includes, but not limited to, chalazia, recurrent styles, pterygium, infection, etc)
- •Any corneal distortion due to previous rigid gas permeable lens wear, surgery or pathology
- •History of any ocular or corneal surgery (e.g. RK, PRK, LASIK)
- •Participation in any pharmaceutical or medical device related clinical trial within 14 days prior to study enrollment.
- •History of binocular vision abnormality or strabismus.
- •Habitual wearers of soft contact lenses in the past 1 month or rigid gas permeable lens within the past 3 months
- •Current habitual use of Prescription Only Medicines (POM) to treat dry eye or ocular discomfort, ocular steroids, or any medication (RX or OTC) that would interfere with the clinical study (at the discretion of the investigator).)
- •Employees of investigational clinic (investigator, coordinator, and technician etc) or family member of an employee of the clinical site by self-report.
- •In addition to the above criteria, patients with any allergy or sensitivity to ingredients that this product may contain (liposomes, sodium hyaluronate, vitamin E polyethylene glycol succinate (TPGS), polyethylene glycol 400 (PEG 400), disodium edetate, polyhexanide methylbiguanide, propylene glycol, boric acid, dimyristoyl phosphatidylglycerol, edetate disodium, hydroxypropyl guar, mineral oil, polyoxyl 40 sterate, polyquaternium-1, sorbitan tristearate, sorbitol, hydrochloric acid and/or sodium hydroxide) should not participate in the study.
研究组 & 干预措施
Test/Control
Experimental
Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
干预措施: Test Eye Drops (Device)
Test/Control
Experimental
Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
干预措施: Control Eye Drops (Device)
Control/Test
Experimental
Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
干预措施: Control Eye Drops (Device)
Control/Test
Experimental
Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
干预措施: Test Eye Drops (Device)
结局指标
主要结局
Ocular Comfort
时间窗: 1-Week Follow-up
Ocular comfort was measured using the visual analogue scale of 0 to 100. Where 0 is extremely uncomfortable and 100 is extremely comfortable.
次要结局
- Subjective Dryness Rating(1-Week Follow-up)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
effect of teaching methods role playing on pregnant women’s knowledge, attitude and decision making in relation to type of deliveryKnowledge and attitude and decision-making.Problem related to education and literacy, unspecifiedIRCT2015092623370N2niversity of Medical Sciences Mashhad, Vice chancellor for research67
已完成
不适用
Investigational Test of a New Sleep SupplementSleepMoodCognitive PerformanceNCT03567343University of Arizona105
终止
2 期
Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing SurgeryStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerNCT01340599Case Comprehensive Cancer Center5
尚未招募
不适用
teaching learning strategies based on learners learning style vs conventional teaching strategyCTRI/2020/06/025645Pooja Gill
已完成
不适用
The Effect of Green Tea or Cocoa Extracts in Endothelial Dysfunction in Patients With Diabetes MellitusArterial HypertensionDiabetes MellitusDiabetic NephropathyNCT01130727University of Campinas, Brazil51